Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
2015
Аутори
Čokić, VladanMitrović-Ajtić, Olivera
Beleslin-Čokić, Bojana
Marković, Dragana
Kovačić, Marijana
Diklić, Miloš
Kraguljac-Kurtović, Nada
Damjanović, Svetozar
Milenković, Pavle B.
Gotić, Mirjana
Raj, Puri K.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The recent JAK1/2 inhibitor trial in myeloproliferative neoplasms (MPNs) showed that reducing inflammation can be more beneficial than targeting gene mutants. We evaluated the proinflammatory IL-6 cytokine and JAK-STAT signaling pathway related genes in circulating CD34(+) cells of MPNs. Regarding laboratory data, leukocytosis has been observed in polycythemia vera (PV) and JAK2V617F mutation positive versus negative primary myelofibrosis (PMF) patients. Moreover, thrombocytosis was reduced by JAK2V617F allele burden in essential thrombocythemia (ET) and PMF. 261 significantly changed genes have been detected in PV, 82 in ET, and 94 genes in PMF. The following JAK-STAT signaling pathway related genes had augmented expression in CD34(+) cells of MPNs: CCND3 and IL23A regardless of JAK2V617F allele burden; CSF3R, IL6ST, and STAT1/2 in ET and PV with JAK2V617F mutation; and AKT2, IFNGR2, PIM1, PTPN11, and STAT3 only in PV. STAT5A gene expression was generally reduced in MPNs. IL-6 cytokin...e levels were increased in plasma, as well as IL-6 protein levels in bone marrow stroma of MPNs, dependent on JAK2V617F mutation presence in ET and PMF patients. Therefore, the JAK2V617F mutant allele burden participated in inflammation biomarkers induction and related signaling pathways activation in MPNs.
Извор:
Mediators of Inflammation, 2015, 2015Издавач:
- Hindawi Ltd, London
Финансирање / пројекти:
- Intramural Research Program at the National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, USA
- Испитивање патогенезе хематолошких малигнитета (RS-MESTD-Basic Research (BR or ON)-175053)
DOI: 10.1155/2015/453020
ISSN: 0962-9351
PubMed: 26491227
WoS: 000362735900001
Scopus: 2-s2.0-84944268561
Институција/група
Institut za medicinska istraživanjaTY - JOUR AU - Čokić, Vladan AU - Mitrović-Ajtić, Olivera AU - Beleslin-Čokić, Bojana AU - Marković, Dragana AU - Kovačić, Marijana AU - Diklić, Miloš AU - Kraguljac-Kurtović, Nada AU - Damjanović, Svetozar AU - Milenković, Pavle B. AU - Gotić, Mirjana AU - Raj, Puri K. PY - 2015 UR - http://rimi.imi.bg.ac.rs/handle/123456789/625 AB - The recent JAK1/2 inhibitor trial in myeloproliferative neoplasms (MPNs) showed that reducing inflammation can be more beneficial than targeting gene mutants. We evaluated the proinflammatory IL-6 cytokine and JAK-STAT signaling pathway related genes in circulating CD34(+) cells of MPNs. Regarding laboratory data, leukocytosis has been observed in polycythemia vera (PV) and JAK2V617F mutation positive versus negative primary myelofibrosis (PMF) patients. Moreover, thrombocytosis was reduced by JAK2V617F allele burden in essential thrombocythemia (ET) and PMF. 261 significantly changed genes have been detected in PV, 82 in ET, and 94 genes in PMF. The following JAK-STAT signaling pathway related genes had augmented expression in CD34(+) cells of MPNs: CCND3 and IL23A regardless of JAK2V617F allele burden; CSF3R, IL6ST, and STAT1/2 in ET and PV with JAK2V617F mutation; and AKT2, IFNGR2, PIM1, PTPN11, and STAT3 only in PV. STAT5A gene expression was generally reduced in MPNs. IL-6 cytokine levels were increased in plasma, as well as IL-6 protein levels in bone marrow stroma of MPNs, dependent on JAK2V617F mutation presence in ET and PMF patients. Therefore, the JAK2V617F mutant allele burden participated in inflammation biomarkers induction and related signaling pathways activation in MPNs. PB - Hindawi Ltd, London T2 - Mediators of Inflammation T1 - Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms VL - 2015 DO - 10.1155/2015/453020 ER -
@article{ author = "Čokić, Vladan and Mitrović-Ajtić, Olivera and Beleslin-Čokić, Bojana and Marković, Dragana and Kovačić, Marijana and Diklić, Miloš and Kraguljac-Kurtović, Nada and Damjanović, Svetozar and Milenković, Pavle B. and Gotić, Mirjana and Raj, Puri K.", year = "2015", abstract = "The recent JAK1/2 inhibitor trial in myeloproliferative neoplasms (MPNs) showed that reducing inflammation can be more beneficial than targeting gene mutants. We evaluated the proinflammatory IL-6 cytokine and JAK-STAT signaling pathway related genes in circulating CD34(+) cells of MPNs. Regarding laboratory data, leukocytosis has been observed in polycythemia vera (PV) and JAK2V617F mutation positive versus negative primary myelofibrosis (PMF) patients. Moreover, thrombocytosis was reduced by JAK2V617F allele burden in essential thrombocythemia (ET) and PMF. 261 significantly changed genes have been detected in PV, 82 in ET, and 94 genes in PMF. The following JAK-STAT signaling pathway related genes had augmented expression in CD34(+) cells of MPNs: CCND3 and IL23A regardless of JAK2V617F allele burden; CSF3R, IL6ST, and STAT1/2 in ET and PV with JAK2V617F mutation; and AKT2, IFNGR2, PIM1, PTPN11, and STAT3 only in PV. STAT5A gene expression was generally reduced in MPNs. IL-6 cytokine levels were increased in plasma, as well as IL-6 protein levels in bone marrow stroma of MPNs, dependent on JAK2V617F mutation presence in ET and PMF patients. Therefore, the JAK2V617F mutant allele burden participated in inflammation biomarkers induction and related signaling pathways activation in MPNs.", publisher = "Hindawi Ltd, London", journal = "Mediators of Inflammation", title = "Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms", volume = "2015", doi = "10.1155/2015/453020" }
Čokić, V., Mitrović-Ajtić, O., Beleslin-Čokić, B., Marković, D., Kovačić, M., Diklić, M., Kraguljac-Kurtović, N., Damjanović, S., Milenković, P. B., Gotić, M.,& Raj, P. K.. (2015). Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms. in Mediators of Inflammation Hindawi Ltd, London., 2015. https://doi.org/10.1155/2015/453020
Čokić V, Mitrović-Ajtić O, Beleslin-Čokić B, Marković D, Kovačić M, Diklić M, Kraguljac-Kurtović N, Damjanović S, Milenković PB, Gotić M, Raj PK. Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms. in Mediators of Inflammation. 2015;2015. doi:10.1155/2015/453020 .
Čokić, Vladan, Mitrović-Ajtić, Olivera, Beleslin-Čokić, Bojana, Marković, Dragana, Kovačić, Marijana, Diklić, Miloš, Kraguljac-Kurtović, Nada, Damjanović, Svetozar, Milenković, Pavle B., Gotić, Mirjana, Raj, Puri K., "Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms" in Mediators of Inflammation, 2015 (2015), https://doi.org/10.1155/2015/453020 . .